You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Phase II Study of Docetaxel and Cisplatin Chemotherapy in 5-Fluorouracil/Cisplatin Pretreated Esophageal Cancer

Shim, Hyun-Jeong MD, PhD*; Cho, Sang-Hee MD, PhD*; Hwang, Jun-Eul MD*; Bae, Woo-Kyun MD*; Song, Sang-Yun MD†; Cho, Sung-Bum MD, PhD*; Lee, Wan-Sik MD, PhD*; Joo, Young-Eun MD, PhD*; Na, Kook-Joo MD, PhD†; Chung, Ik-Joo MD, PhD*‡

American Journal of Clinical Oncology:
doi: 10.1097/COC.0b013e3181bead92
Original Article: Thoracic
Abstract

Background: This study was performed to determine the feasibility and safety of salvage chemotherapy, using docetaxel and cisplatin in 5-fluorouracil (5-FU) and cisplatin-pretreated esophageal cancer.

Methods: Patients with metastatic or recurrent esophageal squamous cell carcinoma that had previously been treated with 5-FU and cisplatin chemotherapy or chemoradiotherapy were eligible for this study. Docetaxel (70 mg/m2) and cisplatin (75 mg/m2) were given as a 1-hour intravenous infusion on day 1, and the treatment was repeated every 3 weeks.

Results: Thirty-eight male patients were enrolled, and 35 patients were available for evaluation. The median age was 64.5 years; Eastern Cooperative Oncology Group performance status was 0/1/2 = 2/18/18. The median and total numbers of cycles delivered were 3.5 (range, 1–9 cycles) and 162, respectively. One patient (2.6%) achieved complete response, 12 (31.6%) achieved partial response, 12 (31.6%) had stable disease, and 10 (26.3%) had progressive disease. The overall response rate was 34.2% (95% confidence interval, 19.6–51.3). The median progression-free survival and overall survival times were 4.5 ± 1.3 months (95% CI, 4.1–4.9) and 7.4 ± 0.4 months (95% CI, 7.3–7.5), respectively. The main hematological toxicities greater than grade 3 were neutropenia and leucopenia in 20 (52.6%) and 18 patients (47.3%), respectively. Nonhematological toxicities greater than grade 3 included asthenia in 12 patients (31.6%), nausea in 7 patients (18.4%), and peripheral neuropathy in 6 patients (15.8%).

Conclusions: Chemotherapy with docetaxel and cisplatin was an effective and feasible treatment following treatment with 5-FU and cisplatin, and would be considered as a salvage option for patients with refractory esophageal cancer.

Author Information

From the Departments of *Internal medicine and †Chest Surgery, and ‡The Brain Korea 21 Project, Center for Biomedical Human Resources, Chonnam National University Medical School, Gwangju, Korea.

Reprints: Ik-Joo Chung, MD, PhD, Department of Internal Medicine, Chonnam National University Hwasun Hospital, 160 Ilsim-ri, Hwasun-eup, Hwasun-gun, Jeollanamdo, Korea. E-mail ijchung@chonnam.ac.kr.

© 2010 Lippincott Williams & Wilkins, Inc.